Recent developments in the diagnosis and treatment of Addison's disease
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20243414Keywords:
AD, PAI, Glucocorticoid replacement, Hydrocortisone, Autoimmune adrenalitis, Adrenal crisisAbstract
Primary adrenal insufficiency (PAI), also referred to as Addison's disease (AD), is a rare but potentially life-threatening disorder marked by a deficiency in the production of hormones by the adrenal cortex. Despite significant advancements in diagnosis and treatment, challenges remain, particularly in pediatric cases where diagnostic delays are common. Autoimmune adrenalitis is the leading cause of AD in adults, while congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is the primary cause in children. Recent developments include dual-release hydrocortisone formulations designed to mimic circadian rhythms and improve patient outcomes, as well as continuous subcutaneous cortisol infusion using insulin pumps. Experimental therapies, such as immunosuppression, gene therapy, and cell replacement, are in early stages of research. Management focuses on hormone replacement therapy and preventing adrenal crises, often triggered by infections or surgery. Education on crisis prevention is crucial, and patients should regularly monitor hormone levels. Advances in treatment aim to improve quality of life, yet more research is needed to refine therapeutic approaches and long-term outcomes.
Metrics
References
Bornstein SR, Allolio B, Arlt W, Andreas B, Andrew DW, Gary DH, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2016;101(2):364-89.
Kirkgoz T, Guran T. Primary adrenal insufficiency in children: Diagnosis and management. Best Pract Res Clin Endocrinol Metabol. 2018;32(4):397-424.
Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. The Lancet. 2021;397(10274):613-29.
Addison T. On the constitutional and local effects of disease of the supura-renal capsules. Highley, London; 1855.
Barthel A, Benker G, Berens K, Sven D, Burkhard M, Matthias G, et al. An update on Addison’s disease. Exp Clin Endocrinol Diabetes. 2019;127(02/03):165-75.
Sarett L. The synthesis of hydrocortisone from desoxycholic acid. J Biol Chem. 1946;162:601.
Capalbo D, Esposito A, Gaeta V, Paola L, Sara V, Raffaella DM, et al. The multiple faces of autoimmune Addison’s disease in children. Frontiers in Endocrinology. 2024;15:1411774.
Meyer G, Neumann K, Badenhoop K, Linder R. Increasing prevalence of Addison's disease in German females: health insurance data 2008-2012. Eur J Endocrinol. 2014;170(3):367-73.
Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison’s disease underestimated? J Clin Endocrinol Metabol. 1999;84(5):1762.
Mitchell AL, Pearce SH. Autoimmune Addison disease: pathophysiology and genetic complexity. Nature Rev Endocrinol. 2012;8(5):306-16.
Husebye ES, Løvås K. Immunology of Addison's disease and premature ovarian failure. Endocrinol Metabol Clin N Am. 2009;38(2):389-405.
Burton C, Cottrell E, Edwards J. Addison's disease: identification and management in primary care. Brit J General Pract. 2015;65(638):488-90.
Bouachour G, Tirot P, Varache N, Gouello JP, Harry P, Alquier P. Hemodynamic changes in acute adrenal insufficiency. Intensive care medicine. 1994;20(2):138-41.
Ho W, Druce M. Quality of life in patients with adrenal disease: A systematic review. Clin Endocrinol. 2018;89(2):119-28.
Hirota Y, Matsushita T. Hyperpigmentation as a clue to Addison disease. Cleveland Clin J Med. 2022;89(9):498-9.
Thawabteh AM, Jibreen A, Karaman D, Thawabteh A, Karaman R. Skin Pigmentation Types, Causes and Treatment-A Review. Molecules (Basel, Switzerland). 2023;28(12):10.
Giannakopoulos A, Sertedaki A, Efthymiadou A, Chrysis D. Addison's disease without hyperpigmentation in pediatrics: pointing towards specific causes. Hormones (Athens, Greece). 2023;22(1):143-8.
Sadaf M, Bryan SQR, Muhammad W. Addison Disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Samuels MH. Effects of variations in physiological cortisol levels on thyrotropin secretion in subjects with adrenal insufficiency: a clinical research center study. J Clin Endocrinol Metabol. 2000;85(4):1388-93.
Herndon J, Nadeau AM, Davidge-Pitts CJ, Young WF, Bancos I. Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine. 2018;62(3):721-8.
Takahashi K, Kagami S, Kawashima H, Kashiwakuma D, Suzuki Y, Iwamoto I. Sarcoidosis Presenting Addison's Disease. Internal Med (Tokyo, Japan). 2016;55(9):1223-8.
Hahner S, Ross RJ, Arlt W, Irina B, Stephanie BS, David JT, et al. Adrenal insufficiency. Nature Rev Dis Primers. 2021;7(1):19.
Saverino S, Falorni A. Autoimmune Addison's disease. Best Pract Res Clin Endocrinol Metabol. 2020;34(1):101379.
Worth C, Vyas A, Banerjee I, Wei L, Julie J, Helen S, et al. Acute Illness and Death in Children With Adrenal Insufficiency. Fronti Endocrinoly. 2021;12:757566.
Kienitz T, Bechmann N, Deutschbein T, Stefanie H, Jürgen H, Matthias K, et al. Adrenal crisis–definition, prevention and treatment: results from a Delphi survey. Hormone Metabol Res. 2024;56(01):10-5.
Autoimmune Polyendocrine Syndromes. N Eng J Med. 2018;378(26):2542-4.
Paparella R, Menghi M, Micangeli G, Lucia L, Giovanni P, Francesca T, et al. Autoimmune Polyendocrine Syndromes in the Pediatric Age. Children. 2023;10(3):588.
Johannsson G, Nilsson A, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metabol. 2012;97(2):473-81.
Nilsson AG, Bergthorsdottir R, Burman P, Per D, Bertil E, Britt EE, et al. Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. Eur J Endocrinol. 2017;176(6):715-25.
Mallappa A, Sinaii N, Kumar P, Martin JW, Lori-Ann D, Dena D, et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metabol. 2015;100(3):1137-45.
Whitaker MJ, Spielmann S, Digweed D, Hiep H, David E, Trevor NJ, et al. Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency. J Clin Endocrinol Metabol. 2015;100(4):1681-8.
Gagliardi L, Nenke MA, Thynne TR, Jenny B, Wayne AR, David EH, et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metabol. 2014;99(11):4149-57.
Øksnes M, Björnsdottir S, Isaksson M, Paal M, Siri C, Roy MN, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial. J Clin Endocrinol Metabol. 2014;99(5):1665-74.
Russell GM, Durant C, Ataya A, Ragini B, Wolfram W, Stafford L, et al. Subcutaneous pulsatile glucocorticoid replacement therapy. Clin Endocrinol. 2014;81(2):289-93.
